At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Navarixin +2 moredrug
Likely dose
Navarixin 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of SCH 527123 in Subjects With Neutrophilic Asthma
In Brief
A Phase 2 clinical trial evaluating Navarixin, Placebo, and 1 other intervention for Neutrophilic Asthma. Completed, enrolled 37 participants.
Detailed Summary
4-Week Safety Study in Subjects with Neutrophilic Asthma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeutrophilic Asthma
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
Enrollment StartMay 2008
Primary CompletionFeb 2009
TodayJul 2026
First PostedMar 10, 2008
Enrollment StartMay 1, 2008
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.3 years ago
Interventions
Navarixindrug
Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.
Placebodrug
Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
Rescue medicationdrug
Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms